Relmada Therapeutics RLMD
NASDAQ RLMD
$3.60 -0.06 (-1.64%)
At close: Oct 2, 2026 · 4:00 PM EDT

Relmada Therapeutics (RLMD) Return on Sales [ROS] (2012 - 2013)

Updated

Relmada Therapeutics (RLMD) reported Return on Sales [ROS] of -877.66% for FY2013, down 725.89 percentage points from -151.77% in FY2012.

Analysis

Relmada Therapeutics (RLMD) Return on Sales [ROS] (2012 - 2013) Analysis & Trends

  • According to Business Quant data, Return on Sales [ROS] came in at -151.77% in FY2012.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROS (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn 51.16%
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn 28.21%
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn 37.86%
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn -3.52%
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn 32.97%
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn 20.57%
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn 34.95%
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn -133.21%
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn 28.37%
10 Relmada Therapeutics 384.01 Mn 384.01 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Nov 30, 2013 -776.97%
May 31, 2013 -3,073.34%
Feb 28, 2013 -176.73%
Nov 30, 2012 -419.73%
Aug 31, 2012 -569.57%
May 31, 2012 -620.25%
API Access

Relmada Therapeutics Return on Sales [ROS] API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=return-on-sales-%5Bros%5D&ticker=RLMD&period=max&api_key=YOUR_API_KEY